New York reports first locally acquired chikungunya case in U.S. since 2019
Source: SeekingAlpha
2025-10-15 13:46:59 ET
More on Valneva, Bavarian Nordic, etc.
- Valneva Outlook: Safety Blow To Ixchiq And Valuation Concerns
- Bavarian Nordic A/S 2025 Q2 - Results - Earnings Call Presentation
- Bavarian Nordic A/S (BVNKF) Q2 2025 Earnings Call Transcript
- Valneva lowers 2025 financial outlook due to loss of Ixchiq vaccine marketing
- Valneva suspended from marketing chikungunya shot in U.S. over safety concerns
Read the full article on Seeking Alpha
For further details see:
New York reports first locally acquired chikungunya case in U.S. since 2019
Bavarian Nordic R/I Ord
NASDAQ: BVNKF
BVNKF Trading
0.0% G/L:
$30.62 Last:
150 Volume:
$30.62 Open:
BVNKF Latest News
July 28, 2025 02:08:04 am
Consortium Led by Nordic Capital and Permira Will Make All-Cash Recommended Purchase Offer for Bavarian Nordic
July 22, 2025 02:00:00 am
Bavarian Nordic Receives Acceptance from Health Canada for Review of the New Drug Submission for its Chikungunya Vaccine
June 18, 2025 03:03:59 am
Bavarian Nordic Announces Sale of Priority Review Voucher for USD 160 Million
BVNKF Stock Data
$2,379,362,265
78,097,834
N/A
N/A
Biotechnology & Life Sciences
Healthcare
DK
Kvistgaard
